Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$760.08
-1.2%
$736.22
$488.45
$779.77
$98.35B1.35581,947 shs463,454 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$1.13
-6.6%
$0.98
$0.61
$5.08
$68.49M1.25214,212 shs183,156 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
-1.30%+0.19%-0.28%+16.27%+30.06%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-6.61%-8.13%+24.59%+17.70%-77.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$760.08
-1.2%
$736.22
$488.45
$779.77
$98.35B1.35581,947 shs463,454 shs
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$1.13
-6.6%
$0.98
$0.61
$5.08
$68.49M1.25214,212 shs183,156 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
-1.30%+0.19%-0.28%+16.27%+30.06%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-6.61%-8.13%+24.59%+17.70%-77.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00
N/AN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
2.68
Moderate Buy$770.941.43% Upside
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
3.00
Buy$4.00253.98% Upside

Current Analyst Ratings Breakdown

Latest PRLD, CCXI, and PH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$809.00
8/29/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
8/19/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/18/2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$4.00 ➝ $3.00
8/15/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Susquehanna
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoveragePositive$860.00
8/8/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/8/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$750.00 ➝ $776.00
8/8/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$735.00 ➝ $845.00
8/8/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$717.00 ➝ $726.00
8/8/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$770.00 ➝ $800.00
8/8/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$790.00 ➝ $810.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$32.22M115.14N/AN/A$4.09 per share12.71
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$19.85B4.89$34.52 per share22.02$107.15 per share7.09
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
$7M9.14N/AN/A$2.39 per share0.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$3.53B$27.1228.0325.953.1917.79%26.80%12.24%10/30/2025 (Estimated)
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$127.17M-$1.64N/AN/AN/AN/A-106.50%-79.07%11/5/2025 (Estimated)

Latest PRLD, CCXI, and PH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
-$0.45-$0.41+$0.04-$0.41N/AN/A
8/7/2025Q4 2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$7.08$7.69+$0.61$7.16$5.10 billion$5.24 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/A
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
$7.200.95%N/A26.55%70 Years
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/AN/AN/AN/AN/A

Latest PRLD, CCXI, and PH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/21/2025
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
quarterly$1.800.96%9/2/20259/2/20259/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.02
4.54
4.47
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
0.55
1.19
0.71
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
N/A
3.68
3.68

Institutional Ownership

CompanyInstitutional Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
81.09%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
82.44%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
79.72%

Insider Ownership

CompanyInsider Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
8.30%
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
0.39%
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
63.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
17871.36 million65.43 millionOptionable
Parker-Hannifin Corporation stock logo
PH
Parker-Hannifin
57,950127.78 million127.28 millionOptionable
Prelude Therapeutics Incorporated stock logo
PRLD
Prelude Therapeutics
12056.60 million20.43 millionOptionable

Recent News About These Companies

Prelude Cuts Q2 Losses and Costs 13%
Prelude Therapeutics Founder Acquires 28% More Stock
Prelude Therapeutics CEO buys $467K in common stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

ChemoCentryx stock logo

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Parker-Hannifin stock logo

Parker-Hannifin NYSE:PH

$760.08 -9.59 (-1.25%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$759.02 -1.06 (-0.14%)
As of 09/12/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Parker-Hannifin Corporation manufactures and sells motion and control technologies and systems for various mobile, industrial, and aerospace markets worldwide. The company operates through two segments: Diversified Industrial and Aerospace Systems. The Diversified Industrial segment offers sealing, shielding, thermal products and systems, adhesives, coatings, and noise vibration and harshness solutions; filters, systems, and diagnostics solutions to ensure purity and remove contaminants from fuel, air, oil, water, and other liquids and gases; connectors used in fluid and gas handling; and hydraulic, pneumatic, and electromechanical components and systems for builders and users of mobile and industrial machinery and equipment. This segment sells its products to original equipment manufacturers (OEMs) and distributors who serve the replacement markets in manufacturing, packaging, processing, transportation, construction, refrigeration and air conditioning, agricultural, and military machinery and equipment industries. The Aerospace Systems segment offers products for use in commercial and military airframe and engine programs, such as control actuation systems and components, engine build-up ducting, engine exhaust nozzles and assemblies, engine systems and components, fluid conveyance systems and components, fuel systems and components, fuel tank inerting systems, hydraulic systems and components, lubrication components, avionics, sensors, pneumatic control components, thermal management products, fire detection and suppression systems and components, and wheels and brakes, as well as fluid metering, delivery, and atomization devices. This segment markets its products directly to OEMs and end users. The company markets its products through direct-sales employees, independent distributors, and sales representatives. Parker-Hannifin Corporation was founded in 1917 and is headquartered in Cleveland, Ohio.

Prelude Therapeutics stock logo

Prelude Therapeutics NASDAQ:PRLD

$1.13 -0.08 (-6.61%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$1.16 +0.03 (+3.01%)
As of 09/12/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.